Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03385226
Title A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (PORT)
Acronym PORT
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University College, London
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR

Facility Status City State Zip Country Details
University Hospital Birmingham Birmingham United Kingdom Details
Velindre Cancer Centre Cardiff United Kingdom Details
University Hospital Coventry Coventry United Kingdom Details
Beatson West of Scotland Cancer Centre Glasgow United Kingdom Details
Guy's & St Thomas' London United Kingdom Details
The Christie Manchester United Kingdom Details
Freeman Hospital Newcastle United Kingdom Details
Nottingham City Hospital Nottingham United Kingdom Details
Churchill Hospital Oxford United Kingdom Details
Southampton University Hospital Southampton United Kingdom Details
Clatterbridge Cancer Centre Wirral United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field